In the News

OHSU Startup, NOUS Imaging, Receives 510(k) Clearance
September 21, 2020
OHSU Startup NOUS Imaging, a medical imaging software company, received 510(k) clearance from FDA for FIRMM Software.

CTIP Accelerator Announces 2020 Winners for Catalyzing Pediatric Innovation Annual Grant Competition
September 4, 2020
Promedix, a company being formed based on OHSU technology developing novel devices and technologies for pediatric patients was one of five innovators selected as winners for CTIP’s fourth Catalyzing Pediatric Grant (CPI) competition.

Dutch firm that licensed OHSU tech gets $31M infusion
August 5, 2020
A biotech company based in The Netherlands that licensed technology from Oregon Health & Science University has raised $31 million in a Series A financing round. Read more.

OHSU establishes remote emergency response critical care network as part of Army-funded project
July 7, 2020
Oregon Health & Science University is establishing an emergency critical care network that could prove indispensable if Oregon experiences a secondary surge or ongoing waves of COVID-19 cases. 

Biotech company that licensed OHSU drug candidate raises $76M 
June 16, 2020
A San Diego biotech company has raised $76 million to develop a therapy to treat multiple sclerosis that came out of a lab at OHSU. Read more.

2020 OHSU Research and Innovation Awards
June 16, 2020
OHSU Technology Transfer and OHSU Collaborations and Entrepreneurship recognizes innovation, entrepreneurship, industry partnership and technology commercialization.

Autobahn Therapeutics Takes Aim at CNS Disorders with $76 Million Series B
Jun. 9, 2020
The company’s work is built on research conducted by Thomas Scanlan, a professor of Chemical Physiology and Biochemistry, OHSU.

Vir Biotechnology Initiates Phase 1 Clinical Trial of VIR-3434 for Chronic Hepatitis B Virus Infection
May 27, 2020

Key to Oregon Study on COVID-19
May 1, 2020
OHSU, the state of Oregon and the OHSU-PSU School of Public Health will conduct a statewide COVID-19 research study to inform the approach for reopening Oregon.

OHSU agrees to relax licensing agreements to speed COVID treatments
Apr. 17, 2020 - Portland Business Journal
Oregon Health & Science University has joined with other research universities to relax traditional licensing rules, with a goal of expediting promising treatments, vaccines and diagnostic tools for COVID-19. Read more.

OHSU expedites promising new technologies to tackle COVID-19
Apr. 16, 2020
Oregon Health & Science University is joining other universities and academic health centers across the country to relax traditional licensing agreements with the goal of expediting the development of promising technologies to diagnose, treat and prevent COVID-19.

BIP COVID-19 Rapid Response RFA
Apr. 1, 2020
OHSU Research & Innovation, in partnership with The Oregon Clinical & Translational Research Institute (OCTRI), OHSU Technology Transfer and OHSU Collaborations and Entrepreneurship, are accepting proposals for basic or clinical research across the translational spectrum that directly addresses COVID-19 from all disciplines. 

2020 Biomedical Innovation Program awards announced
Jan. 8, 2020 - OHSU Research News
Three research projects have been named recipients of the 2020 Biomedical Innovation Program awards. The awards program is a collaboration of the Oregon Clinical and Translational Research InstituteOHSU Technology Transfer, and OHSU Collaborations & Entrepreneurship. The awards provide funds, project management, and mentorship to facilitate the development of innovative technologies at OHSU and accelerate their translation to the marketplace. This track of funding supports translational projects that develop new biomedical devices, diagnostics, and software. Read more.

Recipients of Technology Transfer travel, development awards announced
Dec. 18, 2019 - OHSU Research News
OHSU Technology Transfer introduced two new funding mechanisms in 2019 that support researcher-entrepreneurs in technology development and commercialization. The awards expand Tech Transfer’s portfolio of funding opportunities that support all stages of innovation development — from disclosure through development and commercialization. Read more.

LogicBio Therapeutics extends sponsored research agreement with OHSU to enhance a nuclease-free genome editing technology
Dec. 17 - LogicBio Therapeutics
LogicBio Therapeutics, Inc., a genome editing company focused on developing medicines to durably treat rare diseases in pediatric patients, announced it has entered into an exclusive license with OHSU. The agreement will allow the company to explore methods for enhancing selective advantage of edited hepatocytes using pharmacological agents with the laboratory of  Markus Grompe, M.D., professor of pediatrics, OHSU School of Medicine. This extension phase will focus on translating the enhancement strategy to non-human primates. Learn more.

OHSU startup, PDX Pharmaceuticals, raises $1.5M for cancer drug platform
Dec. 3, 2019 - Portland Business Journal
PDX Pharmaceuticals’ first drug candidate is being developed to treat HER2-positive breast cancer, which accounts for approximately 25 percent of all breast cancers. Current therapies for matastatic HER2-positive breast cancer have severe side effects and patients often develop resistance within a year. PDX Pharmaceuticals received the Series A funding from The Wayne D. Kuni & Joan E. Kuni Foundation , based in Vancouver. The funding is part of a $4 million offering, according to a filing with the U.S. Securities & Exchange Commission. Learn more

OHSU Technology Transfer 2019 Impact Report released
Nov. 30, 2019 - OHSU Technology Transfer
The Fiscal Year 2019 OHSU Technology Transfer Impact Report highlights key achievements and milestones of both the OHSUcommunity and its partners. The overall goal is to work together to translate new technologies and products for public benefit. See how OHSU Technology Transfer is making an impact on the community. Read more

New agreements strengthen research collaborations among Oregon universities
Nov. 19, 2019 - OHSU News
Five Oregon universities have signed new agreements to strengthen collaboration leading to new scientific discoveries. The agreements clarify ownership of intellectual property for discoveries made as a result of research jointly conducted among scientists employed by Oregon Health & Science University, the University of Oregon, Oregon State University, Portland State University, and Oregon Institute of Technology. University leaders say the agreements will ease the ability of scientists to work together to advance scientific discovery, rather than each institution attempting to go it alone. Learn more.

New vaccine against tropical disease yellow fever to be tested
Sept. 30, 2019 - OHSU News
A hydrogen peroxide-based vaccine technology that’s already being tested to fight West Nile Virus will now also be studied to combat the tropical disease yellow fever. Oregon Health & Science University spinoff Najít Technologies, Inc., of Beaverton, Oregon, will test a yellow fever version of the HydroVax vaccine platform it licensed from OHSU. A $3.1-million grant from the National Institutes of Health to Najít will enable Duke University to lead the Phase 1 human clinical trial, and OHSU to study how trial participants’ immune systems respond to the yellow fever vaccine. The trial is expected to start in 2020 and take up to a year to complete. Learn more.

New compound promotes healing of myelin in nervous system disorders
Sept. 6, 2019 - OHSU News
Scientists have developed a compound that successfully promotes the rebuilding of the protective sheath around nerve cells that is damaged in conditions such as multiple sclerosis. In a study published in the journal Glia, scientists described successfully testing the compound in mice. Researchers at Oregon Health & Science University have already started to apply the compound on a rare population of macaque monkeys at the Oregon National Primate Research Center at OHSU who develop a disease that is similar to MS in humans. Learn more.

Better, longer-lasting flu vaccine to be developed at OHSU
Aug. 29, 2019 - OHSU News
The yearly flu shot could become a thing of the past after $12 million in new research that was announced today by the Bill & Melinda Gates Foundation and the charitable organization Flu Lab. Oregon Health & Science University is one of at least six institutions winning a Grand Challenge for Universal Influenza Vaccine Development grant to develop long-lasting and more broadly effective flu vaccines. Such a vaccine could replace the current norm: an annual flu shot that is manufactured six months ahead of time and can miss the mark, causing some of its recipients to still get sick. Seasonal flu outbreaks cause more than a fever and the sniffles – they also lead to an estimated 290,000 to 650,000 deaths annually. OHSU is receiving nearly $1.7 million to adapt its existing vaccine platform, which already is being used to develop vaccines against HIV and tuberculosis, so it can also fight the flu. Learn more.

QuantiPort partners with patent equity fund, Ideaship, to provide physicians with objective blood volume information
July 10, 2019 - MarketsInsider
QuantiPort announced it has received a seed investment from Ideaship, a patent leveraged venture capital firm that provides patent development capital to early stage startups. The investment will support QuantiPort's patent portfolio development related to its disruptive rapid blood volume measurement technology. Learn more

GoCheck Kids nabs $6M for iPhone App that detects amblyopia in pre-verbal children
April 25, 2019 - HitConsultant
Used by over 4,500 pediatricians nationwide, GoCheck Kids is the first iPhone app registered with the U.S. Food and Drug Administration to screen for correctable vision impairments in children under the age of six. GoCheck Kids makes early screen affordable, reducing the cost by over 60 percent. The company has raised $6M in Series B funding led by FCA Venture Partners. Learn more.

OHSU doctors and scientists discover MS breakthrough
April 18, 2019 - kgw
A scientific breakthrough provides new hope for millions of people living with multiple sclerosis. The disease causes your immune system to attack the central nervous system, which damages the myelin, a protective sheath that covers nerve cells in the brain and spinal cord. Researchers at OHSU have developed a compound that stimulates the repair of myelin, which no medicines currently on the market could accomplish. Learn more.

Xoma acquires royalty rights to five hematology assets from Aronora, Inc.
April 8, 2019 - GlobeNewswire
XOMA Corporation (NASDAQ: XOMA) announced today it has agreed to acquire the rights to potential royalty payments and a portion of the potential milestone payments associated with five hematology assets from Aronora, Inc., an OHSU startup. Three of the assets are anti-thrombotic candidates that are covered by a collaboration with Bayer, a global leader in hematology therapeutics. Two of the collaboration assets are in early to mid-stages of development and the third is a Phase 2 candidate that is subject to an option. In addition, XOMA agreed to acquire the rights to potential royalty payments and a portion of the potential upfront and milestone payments associated with two unpartnered hematology programs from Aronora. Learn more.

Archived Stories

OHSU startup MolecularMD is acquired by ICON
Feb. 21, 2019 - MolecularMD

Physician assistant students at Pacific University gain hands-on experience using ReelDx
Nov. 29, 2018 - ReelDx

How OHSU and GE Healthcare are solving a major headache: Patient logistics
Nov. 29, 2018 - Portland Business Journal

Portland health tech startup finds success pivoting back to its roots
Oct. 18, 2018 - Portland Business Journal

Aronora's new blood clot treatment receives FDA Fast Track designation
Sept. 26, 2018 - PR Newswire

Pediatric vision test GoCheck Kids launches for iPhone
Sept. 5, 2018 - MobiHealth News

Three researchers receive 2018 Biomedical Innovation Program drug discovery awards
August 15, 2018 - OHSU Research News

Murdock Trust announces record year of giving
July 5, 2018 - East Oregonian

New device offers solution for ringing ears
July 4, 2018 - NBC Nightly News

How a $600M jolt could get OHSU's promising AIDS vaccine to market
June 14, 2018 - Portland Business Journal

Inside OHSU's $20M quest to deliver the world's first permanent artificial heart to market
Feb. 28, 2018 - Portland Business Journal

Meet the inventor behind OHSU's permanent artificial heart
Feb. 28, 2018 - Portland Business Journal

Innovators meet for the 2017 OHSU Commercialization Conference
Sept. 22, 2017 - OHSU Research News

OHSU scientists find possible roots of severe form of MS
Sept. 18, 2017 - Portland Business Journal

Knight Cancer's Druker on how to go about innovation — and how not to
Sept. 14, 2017 - Portland Business Journal

Portland biotech startup may have the remedy for blood clots
Sept. 7, 2017 - Portland Business Journal

What you need to know about the Oregon-born CRISPR gene-editing breakthrough
Aug. 2, 2017 - Portland Business Journal

OHSU scientists successfully repair genetic mutation in human embryos
Aug. 2, 2017 - Portland Business Journal

At OHSU, healthcare tech is a priority
June 8, 2017 - Innovosource

Researchers moving blood testing from the clinic to the home
April 11, 2017 - OHSU Research News

OCTRI Biomedical Innovation Program, funding for drug discovery
Mar. 3, 2017 - OHSU Research News

OHSU's HIV vaccine technology acquired by Bay Area biotech
Jan. 25, 2017 - The Oregonian

Portland vaccine developer acquired by 'immune programming' startup
Jan. 6, 2017 - Portland Business Journal

David Huang, M.D., Ph.D., receives National Academy of Inventors Award
Dec. 13, 2016 - OHSU Research News

2016 BIP Drug Discovery awardees announced
Jul. 7, 2016 - OHSU Research News

How OHSU's Research Spins Off into Tech Start-Ups
Jun. 24, 2016 - PDX Monthly

OHSU's HIV researcher wins more than $14 million
Jun. 20, 2016 - The Oregonian

Is Portland another Silicon Valley… for Life Sciences?
May 9, 2016 - The Pulse by GE Healthcare

GE Healthcare and OHSU refine their collaboration
Apr. 1, 2016 - Portland Business Journal

OHSU, Intel sign up 2 major cancer centers for ambitious cloud project
Mar. 31, 2016 - Portland Business Journal

Healthtech: Portland startup takes video platform to market
Feb. 23, 2016 - Portland Business Journal

A look at three Oregon health care profs-turned-entrepreneurs
Jan. 15, 2016 - Portland Business Journal

OHSU Spinoff raises $11M to tackle rare brain disease
Jan. 12, 2016 - Portland Business Journal

OCTRI announces 2016 Biomedical Innovation Program award recipients
Jan. 6, 2016 - OHSU Research News

After Intel, OHSU teams with another tech giant to tackle complex research
Nov. 13, 2015 - Portland Business Journal

OHSU Knight Cardiovascular creates company to build first Total Artificial Heart
Nov. 5, 2015 - Portland Business Journal

Apple Announces New ResearchKit Studies for Autism, Epilepsy & Melanoma
Oct. 15, 2015 - Apple, Inc.

New Apple ResearchKit trials focus on epilepsy, autism and skin cancer
Oct. 15, 2015 - Fortune Magazine

Portland startup commercializes OHSU colonoscopy technology
Oct. 9, 2015 - Portland Business Journal

Portland wellness company nets $1.4M NIH grant to help firefighters
Aug. 12, 2015 - Portland Business Journal

Knight Challenge Nets Oregon Health & Science University $1B for Cancer Research
Jun. 25, 2015 - ABC News

OHSU grantees hope to regenerate nerves, create better dental composites and treat breast cancer
Jun. 5, 2015 - Portland Business Journal

First-of-its-kind West Nile virus vaccine now in Phase I clinical trials
May 7, 2015 - OHSU News

OHSU researchers look to patent breakthrough eye test technology
Apr. 21, 2015 - Portland Business Journal

Study shows new technology may improve management of leading causes of blindness
Apr. 20, 2015 - OHSU News

Cover Story: OHSU taps Intel to tackle cancer
Apr. 17, 2015 - Portland Business Journal

Healthtech: Portland Startup will tape your doctor visit so you can watch it later
Apr. 14, 2015 - Portland Business Journal

Report Shows Academia-Industry Technology Transfer Contributed Up to $1.18 Trillion to U.S. Economy Since 1996
Mar. 18, 2015 - Biotechnology Industry Organization

Healthtech: Portland biotech startup forms partnership with pharmaceutical heavyweight
Mar. 6, 2015 - Portland Business Journal

The Pitch: A test to keep the heart pumping
Feb. 13, 2015 - Portland Business Journal

FEI, OHSU expand their partnership for high-powered microscopes
Dec. 15, 2014 - Portland Business Journal

The Pitch: A treatment for severe stroke patients
Dec. 12, 2014 - Portland Business Journal

‘Just pee in a cup’ and other big ideas from OHSU inventors
Nov. 6, 2014 - Portland Business Journal

OHSU conferences aim to bring together inventors, investors and industry
Oct. 28, 2014 - Portland Business Journal

Cover Story: A weight loss pill that could fatten OHSU's wallet
Oct. 3, 2014 - Portland Business Journal

OHSU breaks another record for tech spinoffs
Sept. 19, 2013 - Portland Business Journal

Neuro Kinetics in Tech Transfer Licensing Deal with Oregon Health & Science University
May 16, 2013 - MarketWatch by Wall Street Journal

OHSU Hits Tech Transfer Record
Nov. 23, 2012 - Portland Business Journal

Universities Hitting Tech Transfer Strides
Nov. 21, 2012 - Portland Business Journal

OHSU to Double Tech Transfer Office
Jul. 15, 2011 - Portland Business Journal

MolecularMD adds Two New Clients to Bolster Role as OHSU Tech Transfer Success Story
May 29, 2007 - GenomeWeb